Page 2 - Lupin Ltd News

Lupin gets tentative nod from USFDA for generic HIV treatment drug

Pharma major Lupin Ltd on Wednesday said it has received tentative approval from the US health regulator for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat human immunodeficiency virus (HIV) infection. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets of strength 50 mg/200 mg/25 mg, Lupin said in a regulatory filing. This product would be manufactured at Lupin's Nagpur facility, it added. Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets, 50 mg/200 mg/25 mg are bioequivalent to Biktarvy Tablets, 50 mg/200 mg/25 mg of Gilead Sciences, Inc., and indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg, it added. Citing IQVIA MAT July 2025 data, Lupin said the Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets (Biktarvy) had

Lupin gets US FDA nod for generic drug Lenalidomide in multiple potencies

The announcement comes a day after Lupin said the US FDA had inspected its Nagpur injectable facility between September 8 and 16, issuing six observations

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Lupin, Astra Microwave among top analyst bets; check target, stop-loss

Stocks to buy: Astra Microwave Products has shown a strong movement in the last trading session, while Lupin has recently undergone a notable resurgence

Lupin share price rises 3% as USFDA okays schizophrenia drug; details

Drugmaker Lupin said it has received the USFDA's approval for Risperidone for extended-release injectable suspension

Tariffs, costs, and shifting strategies: Indian pharma's new playbook

Analysts say Indian pharma firms will increase focus on non-US exports and the domestic market as US tariff threats persist, with firms exploring offshore manufacturing options

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Mixed Q1 results for top drug firms amid price erosion, tariff threat

Fresh launches boosted growth for players like Lupin, Torrent

Lupin shares advance 5% after Q1 results; should you buy in?

Lupin shares rose 5 per cent after the firm posted a 52 per cent year-on-year increase in net profit in Q1 FY26

Lupin Q1 results: Net profit jumps 52% to ₹1,221 cr on strong sales in US

Drug maker Lupin on Tuesday posted a 52 per cent year-on-year increase in consolidated profit after tax at Rs 1,221 crore in the June quarter, driven by strong sales in the US and India. The drug maker reported a profit after tax (PAT) of Rs 805 crore in the April-June quarter of last fiscal. Sales rose to Rs 6,164 crore in the first quarter as against Rs 5,514 crore in the year-ago period, Lupin Ltd said in a statement. "We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments," Lupin MD Nilesh Gupta said. "As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth," he added. The company said its sales in the US stood at Rs 2,404 crore in the June quarter, registering a growth of 24 per cent as compared to Rs 1,934 crore in the year-ago period. India sales for Q1 FY26 stood at Rs 2,089 crore, up 8 per cent fr

Q1 results today: Adani Ports, Bharti Airtel, Lupin, 150 others on Aug 5

Q1 FY26 company results, August 5: Britannia, Alembic Pharmaceuticals, Aarti Surfactants, Berger Paints, Bharti Hexacom, and Exide are also to release their April-June quarter earnings reports today

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Stocks to Watch today, July 18: Wipro, Ceat, Axis Bank, LTIMindtree, IHCL

Stocks to Watch today, July 18, 2025: Wipro, LTIMindtree, Lupin and IHCL are some of the key stocks to watch today

Lupin share price increases on rolling out eye medication; details here

Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.

Lupin share pops 2% on licencing and supply agreement with Zentiva; details

Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol.

Lupin launches nasal spray in US, part of 200-drug pipeline by FY30

The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30

Lupin carves out consumer healthcare biz into wholly owned subsidiary

The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges.